AstraZeneca taps China’s CSPC again, betting up to $1.77B to target kidney diseases

Summary

AstraZeneca and CSPC Pharmaceutical Group have entered into another partnership agreement with potential upfront and milestone payments totaling up to $1.77B to develop treatments for kidney diseases, building on prior collaborations in obesity and chronic disease areas.